Neuren Pharmaceuticals Limited

ASX:NEU.AX

12.27 (AUD) • At close November 5, 2024
Bedrijfsnaam Neuren Pharmaceuticals Limited
Symbool NEU.AX
Munteenheid AUD
Prijs 12.27
Beurswaarde 1,568,302,320
Dividendpercentage 0%
52-weken bereik 12.02 - 25.95
Industrie Biotechnology
Sector Healthcare
CEO Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.
Website https://www.neurenpharma.com

An error occurred while fetching data.

Over Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops

Vergelijkbare Aandelen

Opthea Limited logo

Opthea Limited

OPT.AX

0.795 AUD

Monash IVF Group Limited logo

Monash IVF Group Limited

MVF.AX

1.18 AUD

AFT Pharmaceuticals Limited logo

AFT Pharmaceuticals Limited

AFP.AX

3.2 AUD

Sigma Healthcare Limited logo

Sigma Healthcare Limited

SIG.AX

1.975 AUD

Incannex Healthcare Limited logo

Incannex Healthcare Limited

IHL.AX

0.041 AUD

Mayne Pharma Group Limited logo

Mayne Pharma Group Limited

MYX.AX

4.26 AUD

Trajan Group Holdings Limited logo

Trajan Group Holdings Limited

TRJ.AX

1.155 AUD

Capitol Health Limited logo

Capitol Health Limited

CAJ.AX

0.36 AUD

Immutep Limited logo

Immutep Limited

IMM.AX

0.28 AUD

Financiële Gegevens

Cijfers zijn in miljoenen (AUD)

Cijfers zijn in miljoenen (AUD)